In vivo pre-treatment of tumour-derived dendritic cells with anti-CD40 agonist mAb results in therapeutic responses in resistant tumour models when used as vaccination strategies

Research output: Unpublished contribution to conferencePoster

Original languageEnglish
Publication statusPublished - 18 Oct 2019
EventORC day 2019 -
Duration: 18 Oct 201918 Oct 2019


ConferenceORC day 2019

Cite this